vimarsana.com

Page 7 - சமூகம் க்கு நோயெதிர்ப்பு சிகிச்சை ஆஃப் புற்றுநோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |CureVac Announcements | CureVac: CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020

DGAP-News: CureVac / Key word(s): Quarter Results/Annual Results CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 15.04.2021 / 13:30 CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 - COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase 2b/3 in Europe and Latin America fully recruited with over 40,000 participants. Interim analysis for vaccine efficacy expected in Q2 2021 - Phase 2a trial in Peru and Panama amended for addition of secondary endpoint for vaccine efficacy in total population with a focus on participants over the age of 60

CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020

CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 - COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase 2b/3 in Europe and Latin America fully recruited with over 40,000 participants. Interim analysis for vaccine efficacy expected in Q2 2021 - Phase 2a trial in Peru and Panama amended for addition of secondary endpoint for vaccine efficacy in total population with a focus on participants over the age of 60 - CVnCoV demonstrates, in preclinical challenge study, full protection from infections with Variant of Concern B.1.351 (South Africa variant)

SITC to Host Fundamental Two-Day Workshop Focused on Cytokines in Cancer Immunotherapy

Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First

Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.